The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
COMy 2017 | Key findings of the Endeavour study
Evangelos Terpos, MD, PhD, from the University of Athens, School of Medicine, Athens, Greece, discusses the Endeavour study (NCT01568866) at the 2017 World Congress on Controversies in Multiple Myeloma (COMy) in Paris, France. This study compared the progression free survival of dexathasone combined with bortezomib or carfilzomib. The key finding of this study was that dexamethasone plus carfilzomib produced an overall survival advantage, in comparison to dexamethasone plus botezomib.
